Thirteen sexually transmitted human papillomavirus (HPV) subtypes are responsible for all cases of cervical cancer globally (570 000 cases) and a proportion of cases of other anogenital and oropharyngeal cancers (totalling 120 000 cases).
The safety and high efficacy of HPV vaccines have been established in clinical trials. Data are accruing on the effectiveness of HPV vaccination programmes, including strong herd immunity effects, and reduction in cervical cancer rates. HPV vaccination programmes are the cornerstone of the World Health Organization (WHO) Global Strategy on Cervical Cancer Elimination.
This webinar will describe the impact of HPV vaccination in Australia, which implemented one of the earliest and most successful vaccination programmes. This will be followed by an up-to-date overview of global progress in the implementation of HPV vaccination, with a focus on challenges in low- and middle-income countries
Thursday 19 November 2020